Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05285527

MiSight 1 Day Safety Post-Approval Study

The purpose of this post-approval study is to confirm the safety of daily disposable soft contact lens wear among the intended patient population for the MiSight 1 Day lens in the US.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

8 year–12 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Dr. Kit Guan & Associates, Markham, Ontario, Canada

Loading trial locations.

About this study

This prospective post-approval study of safety in a US study population is to confirm the safety of MiSight 1 day lenses. Consecutive subjects receiving the MiSight 1 Day lens, who meet the inclusion criteria, will be prospectively offered to participate in the study. Additionally, safety data from the MiSight 1 Day Post-Approval Study for Effectiveness and Visual Symptoms (PAS001) will be used to supplement this safety study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be between 8 and 12 years of age inclusive at the time of enrollment.
  • Manifest Refraction - Spherical Equivalent Refractive Error (SERE) at baseline between -0.50 D and -7.00 D inclusive (at the corneal plane).
  • Best-corrected visual acuity by manifest refraction of at least 20/25 bilaterally
  • Free of ocular disease or abnormalities (including any corneal scar)
  • The parent/guardian must be capable of comprehending the nature of the study and consent to the use and release of their child's de-identified health care encounter data to be used for purposes of this study. Assent will be obtained from the child in a manner specified by the IRB.
  • Parent/Guardian must sign the Release of Medical Records associated with the outcomes of interest identified from claims data.
  • Interested in wearing contact lenses for approximately 10 hours per day and 6 days per week.
  • Possesses, or obtains prior to dispensing, wearable and visually functional (20/40 or better) eyeglasses.

Exclusion criteria

  • Acute and subacute inflammation or infection of the anterior chamber of the eye.
  • Any eye disease, injury, or abnormality that affects the cornea, conjunctiva, or eyelids.
  • Severe insufficiency of lacrimal secretion (dry eyes).
  • Corneal hypoesthesia (reduced corneal sensitivity), if not aphakic.
  • Any systemic disease that may affect the eye or be exaggerated by wearing contact lenses.
  • Allergic reactions of ocular surfaces or adnexa that may be induced or exaggerated by wearing contact lenses or use of contact lens solutions.
  • Any active corneal infection (bacterial, fungal, or viral).
  • If eyes are red or irritated.
  • The patient is unable to follow lens handling and wear regimen or unable to obtain assistance to do so.
  • In addition to the labeling contraindications, children who are under medication that would interfere with contact lens wear, or who are using any pharmaceuticals for control of myopia will not be included in the study.

Treatment and study plan

MiSight 1 Day

Device

Subjects will wear MiSight 1 day lenses for three years.

Primary outcomes

  1. Incidence of Microbial Keratitis (MK)

    Time frame: 3 years

    Incidence of Microbial Keratitis (MK) ≥ 1 mm

Secondary outcomes

  1. Incidence of peripheral infiltrative keratitis/non-infectious ulcers

    Time frame: 3 years

    Incidence of peripheral infiltrative keratitis/non-infectious ulcers ≤ 1 mm

  2. Incidence of non-infectious infiltrative keratitis

    Time frame: 3 years

    Incidence of non-infectious infiltrative keratitis ≤ 1 mm

  3. Incidence of loss of best-corrected visual acuity

    Time frame: 3 years

    Incidence of loss of best-corrected visual acuity ≥ 2 lines for any adjudicated adverse event.

Sponsors and collaborators

Lead sponsor

CooperVision, Inc.

Industry

Registry information

Important dates

Study start
2022
Primary completion
2030
Study completion
2030
First posted
Mar 17, 2022
Registry last updated
Jul 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.